These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20871406)

  • 1. Small intestinal release mesalamine for the treatment of refractory celiac disease type I.
    Jamma S; Leffler DA; Dennis M; Najarian RM; Schuppan DB; Sheth S; Kelly CP
    J Clin Gastroenterol; 2011 Jan; 45(1):30-3. PubMed ID: 20871406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budesonide Induces Favourable Histologic and Symptomatic Recovery in Patients with Non-responsive and Refractory Coeliac Disease When Given in an Open Capsule Format.
    Saitta D; Henneken LM; Apputhurai P; Chen Yi Mei SL; Tye-Din JA
    Dig Dis Sci; 2024 Jul; 69(7):2548-2557. PubMed ID: 38683433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
    Bonovas S; Nikolopoulos GK; Piovani D; González-Lorenzo M; Pantavou K; Lytras T; Peyrin-Biroulet L; Danese S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2244-2254. PubMed ID: 31269287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesalamine for refractory celiac disease: an old medicine for a new disease.
    Green PH; Lebwohl B
    J Clin Gastroenterol; 2011 Jan; 45(1):1-3. PubMed ID: 21063211
    [No Abstract]   [Full Text] [Related]  

  • 6. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
    Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
    Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-Capsule Budesonide for Refractory Celiac Disease.
    Mukewar SS; Sharma A; Rubio-Tapia A; Wu TT; Jabri B; Murray JA
    Am J Gastroenterol; 2017 Jun; 112(6):959-967. PubMed ID: 28323276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
    Miehlke S; Madisch A; Kupcinskas L; Petrauskas D; Böhm G; Marks HJ; Neumeyer M; Nathan T; Fernández-Bañares F; Greinwald R; Mohrbacher R; Vieth M; Bonderup OK;
    Gastroenterology; 2014 May; 146(5):1222-30.e1-2. PubMed ID: 24440672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features of Adult Autoimmune Enteropathy Compared With Refractory Celiac Disease.
    Sharma A; Choung RS; Wang XJ; Russo PA; Wu TT; Nehra V; Murray JA
    Clin Gastroenterol Hepatol; 2018 Jun; 16(6):877-883.e1. PubMed ID: 29307846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
    United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide in the treatment of refractory celiac disease.
    Brar P; Lee S; Lewis S; Egbuna I; Bhagat G; Green PH
    Am J Gastroenterol; 2007 Oct; 102(10):2265-9. PubMed ID: 17581265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience.
    Maconi G; Mezzina N; Landi S; Grillo S; Bezzio C; Bosani M; Pastorelli L; Dell'Era A; Chibbar R; Carmagnola S; Molteni P; Cassinotti A; Massari A; Ardizzone S
    United European Gastroenterol J; 2019 Nov; 7(9):1164-1170. PubMed ID: 31700629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®
    Danese S; Hart A; Dignass A; Fiorino G; Louis E; Bonovas S; D'Haens G; Dotan I; Rogler G; Paridaens K; Peyrin-Biroulet L
    United European Gastroenterol J; 2019 Nov; 7(9):1171-1182. PubMed ID: 31700630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
    Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
    Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring nonresponsive patients who have celiac disease.
    Krauss N; Schuppan D
    Gastrointest Endosc Clin N Am; 2006 Apr; 16(2):317-27. PubMed ID: 16644460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
    Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies.
    Thomson GT; Thomson BR; Thomson KS; Ducharme JS
    J Rheumatol; 2000 Mar; 27(3):714-8. PubMed ID: 10743814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.